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Abstract
Paracetamol is the most commonly used analgesic in older people, and is mainly dosed according to empirical dosing guide-
lines. However, the pharmacokinetics and thereby the effects of paracetamol can be influenced by physiological changes 
occurring with ageing. To investigate the steps needed to reach more evidence-based paracetamol dosing regimens in older 
people, we applied the concepts used in the paediatric study decision tree. A search was performed to retrieve studies on 
paracetamol pharmacokinetics and safety in older people (> 60 years) or studies that performed a (sub) analysis of phar-
macokinetics and/or safety in older people. Of 6088 articles identified, 259 articles were retained after title and abstract 
screening. Further abstract and full-text screening identified 27 studies, of which 20 described pharmacokinetics and seven 
safety. These studies revealed no changes in absorption with ageing. A decreased (3.9–22.9%) volume of distribution (Vd) in 
robust older subjects and a further decreased Vd (20.3%) in frail older compared with younger subjects was apparent. Like 
Vd, age and frailty decreased paracetamol clearance (29–45.7 and 37.5%) compared with younger subjects. Due to limited 
and heterogeneous evidence, it was difficult to draw firm and meaningful conclusions on changed risk for paracetamol safety 
in older people. This review is a first step towards bridging knowledge gaps to move to evidence-based paracetamol dosing 
in older subjects. Remaining knowledge gaps are safety when using therapeutic dosages, pharmacokinetics changes in frail 
older people, and to what extent changes in paracetamol pharmacokinetics should lead to a change in dosage in frail and 
robust older people.
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Key Points 
Paracetamol is the most commonly used analgesic in 
older people, and is mainly dosed according to clinical 
experience, expert opinions or extrapolated from studies 
in younger adults. However, physiological changes occur 
with increasing age and can thereby influence the phar-
macokinetics and effect of paracetamol.
Based on different non-compartmental pharmacoki-
netic paracetamol studies, decreases in clearance (CL) 
and volume of distribution (Vd) between young adults 
and robust older subjects have been reported, with 
further decreases of CL and Vd in frail older people. 
Consequently, the question should no longer be if these 
changes are statistically significant, but whether the dif-
ference in pharmacokinetic parameters in older subjects 
is clinically relevant enough for dose adaptation.
Based on the—albeit limited—observations retrieved 
in our search, there is no evidence to support a higher 
incidence of hepatotoxicity of paracetamol in normal 
dosages in older subjects. Overall, due to limited and 
heterogeneous evidence, it was difficult to draw firm and 
meaningful conclusions on changed risk for paracetamol 
safety in older people.
Remaining knowledge gaps are safety when using thera-
peutic dosages, pharmacokinetic changes in frail older 
people, and to what extent the changes in paracetamol 
pharmacokinetics should lead to an adaptation in dosing 
in both frail and robust older people.
1 Introduction
Worldwide, 901 million people were aged 60 years or older 
in 2015 [1]. This older population has increased by 48% 
from 2000 and will continue to increase [2]. Obviously, dis-
eases become more prevalent with advanced age and with 
them the use of multiple medications [2, 3]. The use of med-
ication by older people has increased 3- to 5-fold over the 
past decades and is expected to rise even more [4].
Pain (mostly chronic) is one of the most common prob-
lems among older people and a very common indication for 
pharmacotherapy [5, 6]. As older people undergo surgery 
four times more often than younger populations [7], they 
arguably also have a larger probability of acute pain. Thus, 
effective pain management is obviously needed [8]. Unfor-
tunately, older people’s pain is often underreported, under-
estimated and undertreated [9]. Ineffective management is 
partly caused by older people’s changed physiology; that 
is, increased total body fat and decreased kidney function 
[10, 11]. Furthermore, drug dosing is often inappropriate 
because older people (including those with multiple comor-
bidities) are hardly ever included in clinical trials [10, 12]. 
Several guidelines and consensus papers have been written 
to overcome this problem, but these are mostly based on 
clinical experience, expert opinions and current treatment 
extrapolated from studies in younger adults [9].
Paracetamol (acetaminophen, APAP) is the most used 
analgesic in older people; for example, to treat musculo-
skeletal or low back pain [12]. Paracetamol is extensively 
metabolised by different pathways in the liver (Fig. 1) [13]. 
In young adults, paracetamol is metabolised to paracetamol-
glucuronide and paracetamol-sulphate as main metabolites 
(85–90%) [14–16]. Five percent is excreted as unchanged 
paracetamol in urine and 5–10% is oxidised by cytochrome 
P450 (CYP450), primarily by CYP2E1, to a toxic metabo-
lite, N-acetyl-p-benzoquinone-imine (NAPQI) [17]. At 
therapeutic doses, NAPQI is subsequently neutralised by 
glutathione and is excreted as cysteine and mercapturate 
metabolites by the renal route. However, glutathione can 
be depleted, such as in case of an overdose or malnourished 
state, resulting in acute liver damage [18, 19].
Although several guidelines provide dosing advice 
(Table 1), there is no specific focus on older people, either 
robust or frail, and with or without comorbidity. The phys-
iological changes associated with ageing potentially influ-
ences the pharmacokinetics of paracetamol and thereby its 
effects [20]. Furthermore, to have a better evidence base 
for dosing, safety should be considered given the potential 
Fig. 1  Overview of paracetamol metabolism. CYP2E1 cytochrome-
P450 2, GSH glutathione, NAPQI N-acetyl-p-benzoquinone-imine, 
SULT sulphotransferase, UGT UDP-glucuronosyltransferase
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toxicity of one of the metabolites. Therefore, for this spe-
cial population, the key question is what dose should we 
consider as optimal? 
For the paediatric population, the United States Food 
and Drug Administration (FDA) and the European Med-
icine Agency (EMA) proposed a study decision tree to 
guide drug development and to generate evidence-based 
dosing [21, 22]. This decision tree can also be applied in 
other special populations in which physiological changes 
[20] occur, such as older people. This paediatric study 
decision tree consists of an assumption-based framework 
to determine the type of information needed for labelling, 
or to support more evidence-based dosing of existing 
drugs [21, 22]. It enables extrapolation of efficacy, from 
(healthy) young adult data or data in other subpopula-
tions. The assumptions to be considered are similarity in 
disease progression, response to intervention and expo-
sure–response relationships in the paediatric population 
and adults. Pharmacokinetics, pharmacodynamics and/or 
safety studies have to be conducted, taking into account 
the presence or absence of these similarities [21, 22].
When applying this study decision tree in both robust 
and frail older people (Fig. 2), it seems reasonable to 
assume similarities in pain (e.g. postoperative, traumatic, 
chronic) relief response between younger adults and older 
people following similar paracetamol exposure. This is, 
however, an assumption not yet supported by robust data. 
Based on this decision tree, pharmacokinetics and safety 
studies are pivotal to reach safe and effective analgesic 
use of paracetamol in both robust and frail older people 
(Fig. 2 grey boxes). Applying this study decision tree in 
older people minimises the exposure of older people in 
clinical trials and facilitates more timely access to effec-
tive and safe medicines, or at least pharmacokinetics and 
factors influencing pharmacokinetics (e.g. covariates) are a 
prerequisite to explore potential age-dependent differences 
in pain relief response following paracetamol exposure.
Table 1  Dosing suggestions from guidelines and labels for paracetamol for older people
USA United States of America, EU European Union
Dosing advice Maximum daily dose Remark
Guideline or consensus
 American Geriatrics Society 
[62]
325–500 mg every 4 h or 
500–1000 mg every 6 h
4000 mg Reduce maximum dose 50–75% in 
patients with hepatic insufficiency 
or history of alcohol abuse
 British Geriatrics Society [63] 4000 mg
Labels for intravenous administration
 OFIRMEV (USA) [64]
  Adults ≥ 50 kg 1000 mg every 6 h or 650 mg 
every 4 h
4000 mg
  Adults < 50 kg 15 mg/kg every 6 h or 12 mg/kg 
every 4 h
75 mg/kg
 Perfalgan (EU) [65]
  Adults > 50 kg 1000 mg
Minimum interval between each 
administration must be at least 
4 h
4000 mg Minimal interval between each 
administration must be at least 
6 h for patients with severe renal 
insufficiency
No more than 4 doses to be given 
in 24 h
Maximum daily dose is 3000 mg for 
patients > 50 kg with additional 
risk factors for hepatotoxicity
  Adults ≤ 50 kg 15 mg/kg 60 mg/kg not exceeding 3000 mg
Labels for oral administration
 Tylenol® (USA)
  Adults 1000 mg every 6 h 3000 mg
Panadol® (EU) [66]
   Adults > 15 years of age 
and > 55 kg
500–1000 mg, every 4–6 h 3000 mg
  Adults ≤ 55 kg 500 mg, every 4–6 h 3000 mg
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In this review, we applied the study decision tree using 
paracetamol in (a) robust older people and (b) geriatric 
patients (i.e. with frailty, multi-morbidity, polypharmacy), 
and aimed to inventory what is already known of pharma-
cokinetics and safety. Our ultimate goal is to investigate 
which steps are needed to reach evidence-based dosing of 
paracetamol in this heterogeneous and growing population.
2  Methods
2.1  Inclusion Criteria
A search was performed to retrieve studies on paracetamol 
pharmacokinetics and safety in older people or studies that 
performed a sub-analysis of pharmacokinetics and safety 
in older people. Studies on both paracetamol and propa-
cetamol were considered, as propacetamol (no longer mar-
keted in Europe) is a prodrug of paracetamol that is rap-
idly hydrolysed (propacetamol 1 g to paracetamol 0.5 g) by 
plasma esterase [23]. Paracetamol by both intravenous and 
enteral (oral, rectal) routes of administration were consid-
ered for inclusion. Only studies including paracetamol in 
therapeutic dosages were included. Participants were both 
robust older people and geriatric patients (i.e. with frailty, 
multi-morbidity, polypharmacy). Older people included in 
the analysis were defined as those > 60 years of age [1]. To 
pinpoint the potential influence of ageing, studies comparing 
pharmacokinetics and/or safety of older people with that of 
younger subjects were included. The data of younger sub-
jects were also extracted to enable comparison. However, we 
have not performed a fully systematic search on data in peo-
ple < 60 years. Eligible studies were randomised controlled 
trials or observational studies.
2.2  Search Strategy
2.2.1  Electronic Resources
A search was conducted in Embase, Medline Ovid, Web 
of Science, Scopus, Cochrane Library, PubMed Publisher, 
CINAHL EBSCOhost and Google Scholar on 5 October 
2017. No language restrictions were made. Keywords were 
paracetamol/acetaminophen/propacetamol, pharmacokinet-
ics, pharmacodynamics, drug safety, elderly, frail, ageing. 
The search strategy is detailed in Appendix I (see electronic 
supplementary material [ESM]).
2.2.2  Other Resources
References of included studies were checked for relevant 
articles.
Fig. 2  Paediatric study decision 
tree [21, 22] applied to par-
acetamol in older people (grey 
boxes apply). PD pharmacody-
namics, PK pharmacokinetics
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2.3  Study Selection and Data Extraction
Titles and abstracts of retrieved citations were screened for 
relevance by PM, after which full texts of potentially eligible 
studies were obtained. Studies not meeting the inclusion cri-
teria were excluded. In case of doubt, KA was consulted. PM 
extracted the following data from each pharmacokinetics or 
safety study: patient population and study design characteris-
tics such as population, number of patients, age, weight, con-
dition (drugs, medical disorders), paracetamol drug informa-
tion (dose, form), number of samples and study duration. 
For pharmacokinetics studies, ageing-related changes in 
the pharmacokinetics of paracetamol (and its metabolites) 
were extracted, such as clearance and volume of distribu-
tion with or without comparison with younger subjects. For 
safety studies, safety markers (i.e. gastrointestinal, hepatic 
and renal) were extracted with or without comparison with 
younger subjects.
3  Results
3.1  Study Selection and Data Extraction
A total of 6088 potentially relevant studies were identified, 
four of which were obtained through reference checking or 
manual searching. After removal of duplicates, titles and 
abstracts of 4864 were screened for potential relevancy. 
Full texts were obtained for 259 studies, of which 232 
were excluded. The most important reason for exclusion 
was simultaneous analyses of results of young and older 
patients without subpopulation data, or inclusion of only 
younger subjects. Consequently, 27 studies were included, 
of which 20 were pharmacokinetics studies and seven were 
safety studies. Figure 3 outlines the selection flow chart.
Paracetamol pharmacokinetics will be discussed 
first according to the ADME (absorption, distribution, 
Fig. 3  Flowchart of the screen-
ing process Potenally relevant studies
N = 6088
Databases N = 6084
and
Reference check and hand search: N= 4
Potenally relevant studies 
aer removing duplicates
N =4864
Duplicates
N = 1224
Potenally relevant studies 
aer screening tle and 
abstract
N = 259
Potenally relevant 
studies reading full-text 
Included N=27
- PK: 20
- Safety: 7
Excluded studies aer reading full-text:
N = 232
Reasons:
• Only young subjects (N= 66)
• Pooled study outcome of young and   
older subjects (N= 156)
• Duplicates (N=2)
• Case-report (N=2)
• Study protocol (N=2)
• No safety outcome for paracetamol, but 
for other drug (N=3)
PK= pharmacokinecs, N= number
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metabolism, elimination) sequence. Thereafter, safety data 
will be discussed per type of adverse event arising from 
the search, namely hepato-, nephro- and gastrointestinal 
toxicity.
3.2  Pharmacokinetics‑Related Changes 
for Paracetamol in Older People
3.2.1  Characteristics of the Pharmacokinetics Studies
Twenty studies on paracetamol pharmacokinetics were 
included [24–43]. Eighteen reported on pharmacokinetics 
parameters, the other two focused mainly on the amount of 
paracetamol metabolites in older people during prolonged 
administration [34, 35]. Table 2 provides the characteristics 
of the included pharmacokinetics studies. The numbers of 
young and older subjects included in the study ranged from 
6 to 28 and 7 to 30, respectively. When all studies were 
combined, the numbers of young and older subjects were 
172 and 314, respectively. Mean or median age and weight 
of the youth varied from 21 to 30 years and 61 to 81 kg 
and those of the older people from 66 to 89 years and 52 
to 88 kg. Conditions for young and healthy older subjects 
were ambulatory and active. Frail older people were con-
sidered to be dependent of continuous care. The pharma-
cokinetics parameters derived from literature are provided in 
Fig. 4 and Table S2A–C (see ESM) for the individual studies 
as retrieved in the search. Using the ADME sequence, the 
results of these studies are summarised (see Sects. 3.2.2 to 
3.2.4).
3.2.2  Influence of Ageing on Paracetamol Absorption
Only three studies compared the oral bioavailability (F) of 
paracetamol between young and older volunteers based on 
both oral and intravenous administration in a paired analy-
sis [28, 30, 41] (Table S2). F was similar between young 
(mean [SD] 98% [0.3]) and older (95% [11]) subjects, 
as reported by Fulton et al. [41]. Divoll et al., however, 
reported that older subjects tended to show a reduced F of 
both tablets (median [range] 72% [57–95]) and elixir (80% 
[64–94]) compared with younger subjects (79 [59–92] and 
87 [70–106], respectively) [29]. However, statistical signifi-
cance, but not clinical relevance, was attained. In another 
study from Divoll et al., the influence of age on the potential 
food–paracetamol interaction was investigated [28]. When 
paracetamol was administered sober, the F of the elixir 
(median [range] 80% [64–94]) or tablets (72 [57–95]) tended 
to be significantly lower in older subjects compared with 
younger ones (89 [70–106] and 81 [71–92]). When either 
of them was co-administered with food, there were no dif-
ferences between the age groups [28].
Three studies investigated the possibility of an associa-
tion of age with gastric emptying (Table S2, see ESM). They 
found a similar lag time (tlag) and absorption half-life (t1/2abs) 
between younger and older subjects, namely a tlag (median 
[interquartile range] of 0.16  h [0.08–0.20] and 0.16  h 
[0.12–0.22] and a t1/2abs of 0.11 h [0.06–0.18] and 0.12 h 
[0.07–0.33], respectively) [26]. Divoll et al. and Rashid and 
Bateman confirmed these findings [27, 29]. Considering the 
effect of food, the t1/2abs was longer in older subjects taking 
paracetamol elixir (p < 0.05), but not when taking tablets 
(p > 0.05), in comparison with younger subjects. The clinical 
relevance of these results should be interpreted with caution 
because of the large inter-individual variability irrespective 
of age [28].
In conclusion, neither rate nor extent of absorption dif-
fers clinically significantly between young and robust older 
subjects. Absorption was not studied in frail older subjects. 
Therefore, no conclusions can be drawn for this population.
The time at which the maximum concentration is 
achieved (tmax) and the maximum concentration (Cmax) are 
often considered to be absorption-related pharmacokinetics 
parameters. However, these are secondary parameters and 
not solely dependent of the absorption phase. To be consist-
ent with literature, the information per individual study on 
tmax and Cmax is reported in Table S2 below the subheading 
absorption-related parameters (see ESM).
In conclusion, tmax did not change with increased age. For 
Cmax differences between young and robust older subjects 
are less consistent. However, there tend to be no significant 
differences between younger and robust older subjects. No 
information on frail older adults is reported.
3.2.3  Influence of Ageing on Paracetamol Distribution
Nine studies reported on the volume of distribution (Vd) [24, 
25, 29–32, 39–41, 44]. Four studies [37, 38, 42, 43] did 
not report on Vd, but the Vd was calculated based on the 
reported clearance (CL) and half-life (t½). The Vd in younger 
subjects was between 0.77 and 1.40 L/kg and between 0.74 
and 1.08 L/kg in robust older subjects, resulting in a relative 
lower Vd of 3.9–22.9% in the older subjects (Table S2 [see 
ESM], Fig. 4a). However, there is no consistency between 
the studies on the actual statistical or clinical significance 
in comparison with younger subjects. The decreased Vd can 
physiologically be explained by the age-related greater por-
tion of total body weight consisting of fat, which may be 
expected to have a larger influence on lipophilic than on 
hydrophilic drugs. The relative hydrophilic character of par-
acetamol, together with its incomplete distribution into body 
fat, could cause Vd to decrease with age, with a consequent 
rising of paracetamol plasma concentration in older people.
Age is not the only thing responsible for changes in the Vd 
of paracetamol, health condition in the older population can 
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Fig. 4  a Volume of distribution (L/kg), b clearance (L/kg/h) values of 
paracetamol and c formation clearance (L/kg/h) values from paraceta-
mol to its metabolites (in young and older subjects derived from liter-
ature). Notes: For Liukas et al. [39], the clearance values of the older 
subgroups used in their original study (60–70, 70–80, 80–90  years) 
were pooled to obtain one ‘older people’ clearance value. For Ban-
nwarth et al. [37], Kamali et al. [43] and Miners et al. [38], the vol-
ume of distribution was not reported but calculated based on the 
reported clearance and half-life by study
 P. Mian et al.
also affect pharmacokinetics. Wynne et al. studied the asso-
ciation of age and frailty on the Vd (L/kg) of paracetamol. 
They reported the lowest Vd in frail older people, namely 
16.9 and 20.3% lower (not statistically significant) in com-
parison with robust older and young subjects, respectively 
[24]. Ellmers et al. support this finding, be it with only a 
decrease (4.7%) in frail compared with robust older people 
[42], possibly due to small subgroups and a large degree of 
variability within the subgroups. Comparing robust older 
subjects with those with diabetes mellitus, only a small 
decrease (7%) in Vd was noted in older subjects with dia-
betes [43].
Five studies [30–32, 40] investigated sex-related differ-
ences in pharmacokinetic parameters between robust male 
and female older adults, of which four studies reported a 
smaller Vd in women compared with men (p < 0.05), rang-
ing from 8.5 to 17.5% [30–32]. This is probably caused by 
the larger proportion of fat in a woman’s total body weight.
It is reasonable to state that Vd decreases with increasing 
age, most pronouncedly in frail older people. Changes in Vd 
determine the influence of the loading dose, and the elimi-
nation half-life. Both statistical and clinical significance are 
still unknown.
3.2.4  Influence of Ageing on Paracetamol Metabolism 
and Elimination
Eleven out of 13 studies reported reduced paracetamol CL 
(29–45.7%), varying from 0.20 to 0.38 L/h/kg in robust older 
subjects and 0.28 to 0.7 L/h/kg in younger subjects (Fig. 4b, 
Table S2 [see ESM]), while Miners et al. [38] and Triggs 
et al. [25] reported no significant differences. Another study, 
comparing paracetamol CL on days 1 and 7 during repeated 
administration, reported no paracetamol accumulation. 
However, this does not imply anything regarding possible 
accumulation of the (toxic) metabolites.
Additional factors besides age, such as disease, concomi-
tant medication or general physical status (e.g. frailty), may 
influence paracetamol metabolism. Ellmers et al. reported 
a significant decrease (26.4%) in paracetamol CL in frail 
compared with robust older subjects [42], which was sup-
ported by Wynne et al. when paracetamol CL was expressed 
in terms of body weight [24]. Paracetamol CL was 46.8% 
lower in frail older subjects compared with young subjects 
(p < 0.01) and 32.4% lower compared with robust older sub-
jects (p < 0.01). When CL was expressed per unit volume of 
liver, no significant differences were found between young 
and robust older subjects, but it was significantly reduced in 
the frail subjects: 37.5 and 32.9% lower when compared with 
young and robust older cases, respectively. This indicates 
that frailty and/or disease state also decreases CL. No dif-
ference (4%) in paracetamol CL was reported between older 
subjects with and without diabetes [43].
A few pharmacokinetics studies focused on the contribu-
tion of the different metabolic routes (Fig. 4c), with conflict-
ing results. Miners et al. reported no significant change in the 
formation fraction to glucuronide and to oxidative metabo-
lites [38]. However, formation fraction to sulphate and the 
excretion of unchanged paracetamol was 18.2 and 30.0% 
lower in older subjects compared with their younger coun-
terparts [38]. Pickering et al. reported a significant decrease 
in the amount of sulphate excreted in urine in participants 
aged ≥ 65 years but not in those < 65 years, with a decrease 
in glutathione reserves and some more oxidative metabolites 
(p > 0.05) [35]. Next to a significant 36.4% decrease in frac-
tion of sulphate (in robust older vs young subjects), another 
study reported also a significant 13.3% decrease in forma-
tion fraction of glucuronide (in robust older vs young sub-
jects), but reported no differences in excretion of unchanged 
paracetamol between young and robust older subjects [24]. 
The oxidative metabolites were not measured. However, 
when calculating the fraction based on the fact that this is 
the remaining unexplained part of the total paracetamol CL, 
there seems to be no difference between young and robust 
older subjects. For frail older subjects, the formation frac-
tions of glucuronide and sulphate were decreased compared 
with the young (60 and 40%, respectively) and robust older 
subjects (53.9 and 5.7%, respectively) [24]. For older peo-
ple with diabetes, a significant decrease in formation frac-
tion to sulphate (33.3%) and a significant increase in renal 
excretion of unchanged paracetamol (50%) compared with 
robust older subjects were reported. The formation fraction 
of glucuronide remained unchanged.
In conclusion, paracetamol CL decreases not only with 
age but even more with frailty and/or disease state. Conflict-
ing and limited results about the fractions of paracetamol 
into the different metabolic pathways still exist.
A secondary pharmacokinetics parameter, t½, is directly 
related to Vd and inversely to CL. This parameter will not be 
discussed in the text but is reported in Table S2 (see ESM) 
for the individual studies.
3.3  Safety‑Related Changes for Paracetamol 
in Older People
Seven studies reported on adverse events (hepatotoxicity, 
nephrotoxicity and gastrointestinal toxicity) [45–51], possi-
bly related to paracetamol use in older subjects. The studies 
are presented in detail in Table 3 while patterns of safety-
related changes in older people are summarised below.
Paracetamol hepatotoxicity has been investigated in 
multiple studies, but with only a few studies focusing 
on age. Mitchell et al. reported that alanine aminotrans-
ferase (ALAT) concentrations in the frail older and robust 
older subjects were within and slightly above the refer-
ence range, respectively, while the highest serum ALAT 
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concentrations were observed in the younger subjects [45]. 
Although frail older adults received the lowest dosages 
of paracetamol, paracetamol concentrations were high-
est in this group [45] (Table 3). In patients > 65 years of 
age, Jahr et al. found no significant differences in liver 
enzyme values between the paracetamol and placebo 
groups (Table 3) [46]. The overall incidence of adverse 
events was comparable between the paracetamol and pla-
cebo groups and between the young and older subjects. 
A detailed overview of all the adverse events specified in 
the three individual studies can be found in the paper of 
Jahr et al. [46].
One study investigated the effect of paracetamol, 
parecoxib and placebo on the renal function in older peo-
ple [48] (Table 3). No significant decrease in creatinine 
CL was observed in both the paracetamol group and pla-
cebo group. For all treatment groups, urine albumin, α-1-
microglobulin, sodium and potassium were slightly, but 
not significantly, increased.
Four retrospective studies [47, 49, 51, 52] explored the 
association between paracetamol use and gastrointestinal 
toxicity, of which two studies reported no significant dif-
ferences in paracetamol use between hospitalised patients 
and controls with gastrointestinal bleeding [47, 49] or 
duodenal ulcer bleeding [49]. Rahme et al. concluded that 
(after adjustment for ‘risk susceptibility’—likelihood of 
receiving paracetamol e.g. older, sicker, with prior gastro-
intestinal events) patients who took higher-dose paraceta-
mol (2601–3250 or > 3250 mg/day) were more likely to 
experience a gastrointestinal event compared with those 
who took low-dose paracetamol (≤ 2600 mg/day) [51]. 
These higher-dose paracetamol users experienced simi-
lar rates of gastrointestinal events as patients who took a 
high-dose non-steroidal anti-inflammatory drug (NSAID) 
[51]. Another study by Rahme et al. reported an increased 
(non-significant) risk of gastrointestinal events in the high- 
versus low-dose paracetamol group without a proton pump 
inhibitor (PPI); this risk was slightly less when the low-
dose group used a PPI. The highest risk was in the combi-
nation group of NSAID and paracetamol with or without 
a PPI (Table 3) [52].
In conclusion, a very limited number of studies con-
cluded that paracetamol administration at therapeutic doses 
(3000–4000 mg/day) did not result in elevated liver enzymes 
in older people and that glomerular and tubular functions 
were transiently affected in all older people after orthopaedic 
surgery. However, the effects were limited and not signifi-
cant. The evidence concerning the increased risk of gastro-
intestinal events after paracetamol usage remains inconsist-
ent and therefore not convincing. Overall, due to limited 
and heterogeneous evidence, it was difficult to drawn firm 
and meaningful conclusions on changed risk in paracetamol 
safety in older people.
4  Discussion
In this review, we applied the paediatric study decision 
tree [21, 22] extrapolated to robust and frail older people 
for paracetamol. Based on this study decision tree con-
cept, we performed a search on what is already known on 
pharmacokinetics and safety to delineate the knowledge 
gaps. Our ultimate goal is to describe a roadmap to reach 
evidence-based dosing advice for this heterogeneous and 
increasing population. Concerning the pharmacokinetics 
studies of paracetamol in older subjects, many (n = 20) 
non-compartmental pharmacokinetics analyses were per-
formed (Table 2 and Table S1 [see ESM]), most of which 
compared paracetamol pharmacokinetics between young 
and (robust) older subjects. The limited number of stud-
ies (n = 3) included in this review revealed no changes 
in absorption with ageing [28, 29, 41]. In contrast, the 
Vd was decreased in older subjects and even further 
decreased in frail older subjects compared with younger 
subjects. (Table S2 [see ESM], Fig. 4a). Similar to Vd, age 
and frailty are associated with reduced paracetamol CL 
(Table S2 [see ESM], Fig. 4b). This review reveals that 
pharmacokinetics-related knowledge gaps still remain, and 
these will be discussed below. Thereafter, we will focus on 
what is already known on safety and subsequently high-
light the safety-related knowledge gaps.
Although this review showed cumulative evidence 
around the impact of age and frailty on pharmacokinet-
ics parameters, re-illustration of the importance of other 
factors in this special population of older adults, such as 
drug- and patient-specific factors (e.g. potential covari-
ates) that could influence paracetamol pharmacokinetics 
are underreported or unknown. For drug-specific fac-
tors, limited research, especially on absorption, has been 
conducted on paracetamol when rectally administered in 
robust and frail older subjects. In addition, new routes of 
administration (buccal) are investigated, which should 
also be investigated in relation to the pharmacokinetics 
of oral and/or intravenous routes [53, 54]. Concerning 
the patient-specific factors, the older patient population 
is very heterogeneous (e.g. robust, frail, polypharmacy 
comorbidities). When focusing on robust older subjects, 
the focus of the performed pharmacokinetics studies is 
mainly on the question of whether a significant difference 
in pharmacokinetics parameters exists between the above-
mentioned group and young subjects. This is certainly 
important when performing a first pharmacokinetics study. 
However, this review revealed differences in pharmacoki-
netics parameters such as Vd and CL between young and 
older robust subjects. Consequently, the question should 
no longer be if the difference is statistically significant, 
but whether the difference in CL and/or Vd in robust older 
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subjects is clinically relevant enough for dose adaptation 
in older people.
Population pharmacokinetics modelling can be a useful 
tool, not only to predict pharmacokinetics parameters, but 
also to develop more evidence-based dosing in special popu-
lations [55]. Patient-related (i.e. age, frailty, multi-morbidity, 
polypharmacy) and treatment characteristics (i.e. route of 
administration) can thereby be used to (partly) understand 
and explain the inter-individual and intra-individual variabil-
ity in these pharmacokinetics parameters in older subjects. 
Therefore, those covariates can be used to determine if and 
how dosing can be individualised. After the development 
of such a pharmacokinetics model, the dosage needed to 
reach a specific target concentration can be developed. The 
target concentration  (Cssmean) to reach analgesia is 10 mg/L 
[56]. This specific value as a target concentration in older 
subjects is not specifically investigated, but can be assumed 
to be similar. After the development of a pharmacokinetics 
model and model-based dosing, it would be of the utmost 
importance to prospectively validate the model-based dosing 
in a clinical study, not only to investigate whether the target 
concentration is reached, but also to investigate if the safety 
values are within the reference range. A first step could be 
to evaluate the already performed pharmacokinetics studies 
on quality and the amount of data, such as clinical charac-
teristics, drug concentrations in plasma, number of patients 
and time of sampling, retrieved from these studies in order 
to perform a pooled-pharmacokinetics analysis [55]. Such 
a pooled analysis has already been performed by Allegaert 
et al. [57] with the aim to study all common covariates in 
adults in datasets on intravenous paracetamol. In this way, 
a pooled analysis could be performed with all pharmacoki-
netics data of the older population. After developing a phar-
macokinetics model specific for older people, a next step 
could be to design a new study with specific focus on, for 
example, additional covariates that have not yet been studied 
in already published datasets and that could possibly explain 
the residual variability. In this way, we should use these 
already available datasets and published Pop pharmacokinet-
ics models to put new datasets into these perspectives. This 
is a very effective approach to explore additional covariates 
or specific subpopulations, but should be preceded by a criti-
cal assessment of the published models [39, 58].
After this information has been collected for the more 
homogenous population within the older population, stud-
ies can be extended to investigate the influence of frailty 
on the pharmacokinetics of paracetamol. Until now, only 
two studies have investigated the difference in paracetamol 
pharmacokinetics in robust versus frail subjects; clear dif-
ferences were found between these two older populations 
[24, 42]. However, a major limitation of these studies is 
the small number of study participants. Besides, the defini-
tion of frailty has since changed, as described in the recent 
EMA reflection paper on physical frailty [59]. Ellmers et al. 
defined frailty as immobility (scale 1–5) and living depend-
ently, while Wynne et al. defined frail patients as continu-
ously needing hospital care due to chronic disabling condi-
tions (cerebrovascular or musculoskeletal disease). Despite 
the limited definitions of frailty, differences in pharmacoki-
netics parameters between fit and frail existed. Likewise, 
it has not been investigated if and how dosages should be 
adapted based on the pharmacokinetics in frail older sub-
jects. Lastly, the influence of common multi-morbidity and 
polypharmacy in older people on the pharmacokinetics of 
paracetamol has not yet been investigated.
Another knowledge gap that needs to be further explored 
is the extent of accumulation of paracetamol and its metabo-
lites, especially the active toxic metabolite of paracetamol, 
NAPQI (Fig. 1). Bannwarth et al. found no accumulation 
of paracetamol after 7 days of therapeutic paracetamol dos-
ing [37]. However, future studies should not only focus on 
paracetamol, but also on the toxic metabolite. Data on the 
fraction of formation of paracetamol into its metabolites are 
still limited and conflicting (Fig. 4c) and should therefore be 
investigated. Based on the limited studies focusing on the 
formation CL of the different metabolites, it seems that age-
related changes mostly relate to reduced conjugation capac-
ity, rather than to the formation of the oxidative metabolite. 
This review shows that most studies used high-performance 
liquid chromatography analysis to measure paracetamol as 
well as its metabolites. By using this method it is difficult to 
quantify oxidative metabolites due to assay sensitivity issues 
[13]. As ultra-performance liquid chromatography–mass 
spectrometry techniques are available (and validated) to 
measure paracetamol and all metabolites, these can be used 
in future studies [13].
Compared with the large number of pharmacokinetics 
studies performed, very few studies addressed the safety 
of paracetamol when administered at regular doses. One 
of the main concerns, in any population, is the risk of 
hepatotoxicity [17]. A source of information concerning 
age-related changes to toxicological mechanisms in par-
acetamol is reported by Mitchell et al. [60]. Raised values 
of liver enzymes have been reported even when paraceta-
mol was administered at normal dosages in healthy adults 
[61]. Based on the—albeit limited—observations retrieved 
in our search, there is no evidence that supports a higher 
incidence of hepatotoxicity in normal paracetamol dosages 
in older subjects [45, 46]. This is in line with the fact that 
age-related changes in paracetamol formation CL mostly 
occur in impaired conjugation rather than in the formation 
of oxidative metabolites [24, 35, 38]. Overall, due to limited 
and heterogeneous evidence, it was difficult to draw firm 
and meaningful conclusions on changed risk in paracetamol 
safety in older people. Safety of paracetamol (i.e. hepatic, 
gastrointestinal) should be investigated more profoundly, 
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preferably simultaneously with pharmacokinetics, in clini-
cal trials but also in the clinical setting.
5  Conclusion
Differences in paracetamol CL and Vd between young and 
robust older people have been reported, with an even fur-
ther decrease in those pharmacokinetics parameters in frail 
older people. Based on the—albeit limited—observations 
retrieved in our search, there is no evidence that supports a 
higher incidence of hepatotoxicity in paracetamol at normal 
dosages in older subjects. Overall, due to limited and hetero-
geneous evidence, it was difficult to drawn firm and mean-
ingful conclusions on changed risk for paracetamol safety in 
older people. Population pharmacokinetics modelling can be 
considered a valuable tool to develop more evidence-based 
dosing advice for older people. In addition, more clinical 
studies with enriched clinical characteristics (e.g. comorbid-
ity, comedication, frailty) should be conducted to study both 
the pharmacokinetics of paracetamol (and its metabolites) 
and its safety parameters.
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